top of page
Goals Magazine
More...
Use tab to navigate through the menu items.
Subscribe Now
Get the Magazine
Log In
All Posts
Goal Setting
National News
World News
Entertainment
Business
Style
Sponsor Article
Science
Sports
Search
Johnson & Johnson Will Acquire Eye-Drug Developer Ollin Biosciences in a $2.2 Billion Deal
Ollin Biosciences, a three-year-old developer of eye disease treatments, has agreed to be acquired by Johnson & Johnson for $2.2 billion upfront plus up to about $1.1 billion in milestones.
Joseph Bonner
23 hours ago
3 min read
bottom of page